drugset
drugset / Trial / NCT05611372

Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

NCT05611372 ↗

Phase 2/3 Withdrawn Second Affiliated Hospital, School of Medicine, Zhejiang University Beijing Tiantan Hospital · collabFujian Medical University Union Hospital · collabGuizhou Medical University · collabHuashan Hospital · collabJiangsu Province Nanjing Brain Hospital · collabQilu Hospital of Shandong University · collabSecond Affiliated Hospital of Soochow University · collabSir Run Run Shaw Hospital · collabThe Affiliated Hospital of Hangzhou Normal University · collabThe First Affiliated Hospital of Anhui Medical University · collabThe First Affiliated Hospital of Dalian Medical University · collabThe First Affiliated Hospital of Guangzhou Medical University · collabWest China Hospital · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate whether a year of rasagiline may reduce the progression from idiopathic REM sleep behavior disorder (RBD) to Parkinson's disease (PD).

Timeline

Start
2023-01-01
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule 1 mg —

Indications

Parkinson disease REM sleep behavior disorder synucleinopathy